---
title: "ALK"
slug: "alk"
date: "2023-11-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[alectinib]]

# ALK

[[ALK ASCO recommendation]]

## ALK fusion

- 4% of ADCL,
- a/w younger males,
- never-smoking hx,
- various ALK fusion partners (EML4-ALK most common),
- Sn to ALK kinase inhibitors (NEJM 2010;363:1693)

## treatment

- Initial tx:
  - Alectinib (ORR 83%, PFS 34.8 mos) (NEJM 2017;377:829),
  - brigatinib (ORR 74%, PFS 24.0 mos),
  - ceritinib,
  - or lorlatinib (ORR 76%)
- Subsequent tx:
  - Lorlatinib if previously treated w/ [[alectinib]] or [[brigatinib]];
  - consider [[alectinib]], [[ceritinib]], or brigatinib if previously treated w/ crizotinib. Rebiopsy may guide agent choice based on resistance mts

## Slides 

- [[alki in nsclc.md|ALKi in NSCLC]]

### Backlink

- [[non-small cell lung cancers]]
- [[mechanisms and sites of action of some of the drugs used in the treatment of cancer]]
- [[inpatient oncology]]
- [[alectinib]]
- [[WHO Classification of Lymphoid Malignancies]]
- [[Oncology - Inpatient Oncology - Fast Facts  NEJM Resident 360]]
- [[NSCLC]]
- [[NSCLC Treatment]]
- [[Molecular biology-of-NSCLC]]
- [[Genetics of Diagnostic and staging evaluation of lung cancer]]
- [[Autoimmune Etiologies of Liver Disease]]
- [[Adeno or Other in Stage IV NSCLC Treatment]]
